25.27

1.48% -0.38

After Hours: 25.40 0.13 +0.51%

Mineralys Therapeutics Inc (MLYS)

Overview News Price History Option Chain Financials Discussions Forecast

Mineralys Therapeutics Inc stock is traded at $25.27, with a volume of 590.09K. It is down -1.48% in the last 24 hours and down -5.39% over the past month. Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Previous Close:

$25.65

Open:

$25.68

24h Volume:

590.09K

Relative Volume:

0.43

Market Cap:

$2.23B

Revenue:

Net Income/Loss:

$-151.78M

P/E Ratio:

-12.27

EPS:

-2.0595

Net Cash Flow:

$-136.42M

1W Performance:

-2.99%

1M Performance:

-5.39%

6M Performance:

-15.65%

1Y Performance:

+69.77%

1-Day Range:

$24.95

$25.86

1-Week Range:

$24.95

$27.75

52-Week Range:

$14.53

$47.65

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name

Mineralys Therapeutics Inc

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

(888) 378-6240

Address

150 N. RADNOR CHESTER RD., RADNOR

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

MLYS's Discussions on Twitter

Compare MLYS vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLYS Mineralys Therapeutics Inc	25.27	2.28B	0	-151.78M	-136.42M	-2.0595
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-27-26	Initiated	TD Cowen	Buy
Jun-11-25	Initiated	Jefferies	Hold
Jul-10-24	Initiated	H.C. Wainwright	Buy
Apr-02-24	Initiated	Goldman	Buy
Mar-07-23	Initiated	BofA Securities	Buy
Mar-07-23	Initiated	Credit Suisse	Outperform
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Guggenheim	Buy
Mar-07-23	Initiated	Stifel	Buy
Mar-07-23	Initiated	Wells Fargo	Overweight

View All

Mineralys Therapeutics Inc Stock (MLYS) Latest News

Aug 21, 2026

Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal - Stock Titan

Aug 21, 2026

Aug 20, 2026

Mineralys Plunges As Costly Royalty Deal Shocks Wall Street - TipRanks

Aug 20, 2026

Aug 19, 2026

People on the Move: Jessica Wagner Keliher, SPHR, Joins Mineralys Therapeutics as Vice President, Talent Management - BioBuzz

Aug 19, 2026

Timothy G. Youngquist 2020 Irrevocable Trust Takes $2.72 Million Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat

Aug 19, 2026

Aug 18, 2026

TimesSquare Capital Management LLC Invests $6.36 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat

Aug 18, 2026

Aug 17, 2026

Mineralys (NASDAQ: MLYS) insider adds 417-share sale to six-figure run - Stock Titan

Aug 17, 2026

Aug 16, 2026